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Purpose: This study investigated the impact of changing availability of tamper‐deterrent and
non‐tamper‐deterrent oxycodone on prescribing patterns of controlled‐release oxycodone across
Canada.
Methods: We conducted a population‐based, serial cross‐sectional study of controlled‐
release oxycodone dispensing from community pharmacies across Canada between October
2007 and April 2016. We calculated rates of dispensing (tablets per 100 population) and reported
the relative market share of generic non‐tamper‐deterrent controlled‐release oxycodone. All
analyses were reported nationally and stratified by province.
Results: After the introduction of a tamper‐deterrent formulation, the national rate of con-
trolled‐release oxycodone dispensing fell by 44.6% (from 26.4 to 14.6 tablets per 100 population
from February 2012 to April 2016). Between December 2012 and July 2013, there was moderate
uptake of generic non‐tamper‐deterrent controlled‐release oxycodone (968 452 tablets; 16.0% in
July 2013), which appeared to have little impact on the overall rate of controlled‐release oxyco-
done dispensing in Canada. However, the uptake of generic non‐tamper‐deterrent oxycodone
varied considerably by province. By April 2016, 55.0% of all controlled‐release oxycodone tablets
dispensed in Quebec were for the generic formulation. Elsewhere in Canada, this prevalence was
less than 30%, ranging between 1.6% (Prince Edward Island) and 26.9% (British Columbia) at the
end of our study period.
Conclusions: The changing availability of tamper‐deterrent and non‐tamper‐deterrent for-
mulations of controlled‐release oxycodone in Canada has had variable influence on the rate of
use of these products across Canada. Future research should explore whether the availability
of generic controlled‐release oxycodone has led to measurable changes in the safety of oxyco-
done use in Canada.
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Opioids are a class of drugs that have been traditionally used to treat
acute and chronic pain. Despite fairly stable prescribing patterns in
the 1980s and early 1990s, opioid prescribing rose dramatically in
Canada following the approval of OxyContin,1 a controlled‐release- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Pharmacoepidemiol Drug Saf. 2018;27:520–525.
KEY POINTS
• The introduction of a tamper‐deterrent formulation was
associated with a 44.6% reduction in overall dispensing
of controlled release oxycodone.
• There was moderate uptake of generic, non‐
tamper‐deterrent oxycodone; however, this did not
lead to an expansion in the overall prescribing rate of
controlled‐release oxycodone.
• By 2016, 1 in 5 tablets for controlled‐release oxycodone
that were dispensed in Canada were for a generic, non‐
tamper‐deterrent form.
GOMES ET AL. 521formulation of oxycodone in 1996. This was largely attributed to an
intense marketing campaign by OxyContin's manufacturer, which pro-
moted the use of controlled‐release opioids for the treatment of chronic
noncancer pain, with claims of minimal risk of addiction.2,3 Over the
subsequent decade, the addiction potential of controlled‐release opioid
formulations was realized, evidenced by an epidemic of prescription
opioid misuse and related overdose deaths across North America.1,4-6
Since this time, policies have been introduced across Canada to
address the rising use of oxycodone and its potential for misuse. These
have included restricted access on some provincial drug programs and
the introduction of safety warnings on product monographs.7,8 In
February 2012, the manufacturer of OxyContin introduced a tamper‐
deterrent formulation of controlled‐release oxycodone (OxyNeo)
across Canada and ceased production of their original product.9
Although this new formulation does not protect against developing
an opioid addiction or accidentally overdosing when ingesting the drug
orally, it was designed to be more difficult to crush, chew, or dissolve
thus introducing barriers to its misuse.9 The introduction of this
product coincided with restricted listing status of controlled‐release
oxycodone products on the public formularies in several provinces
(Appendix S1).7 In November 2012, the oxycodone prescribing
landscape shifted again when the patent for OxyContin expired, and
Health Canada approved generic forms of controlled‐release oxyco-
done without tamper‐deterrent properties.10 In Australia, a similar
decision to Canada was implemented in 2014. A published conference
paper reported that the introduction of the tamper‐deterrent form of
oxycodone led to some switching to other opioids, but the authors
found no discernible additional impact of the introduction of the
generic products on opioid‐switching patterns.11 In contrast, in the
United States, the Food and Drug Administration announced that it
would not approve any forms of generic OxyContin because of con-
cerns that the risks outweighed the benefits of this non‐tamper‐
deterrent form of controlled‐release oxycodone.12 The approval of
these drugs in Canada led to debate regarding the safety of
reintroducing non‐tamper‐deterrent oxycodone to the market and
decisions on the part of many Canadian provincial drug programs
against listing the generic formulations on their formularies.13-15 The
generic long‐acting forms of oxycodone are marketed in all Canadian
provinces and can be prescribed by a registered medical practitioner
(and in some provinces, a nurse practitioner) to any patient who is
believed to need a controlled drug for pain relief. The prescription
may be subject to special monitoring (eg, systems to avoid inappropri-
ate “double doctoring,”which vary by province) and the patient, and/or
their insurer, is responsible for covering the dispensed drug price. For
example, the cost of 100 tablets of 20‐mg generic long‐acting oxyco-
done is approximately $66 plus a pharmacist's professional fee. In
Canada, the generic drug is covered by only 2 provincial public drug
plans, Quebec and Nova Scotia (see Appendix S1), which have dif-
ferent levels of premiums, co‐payment, and deductibles. In Quebec,
patients can request a generic drug formulation from their pharma-
cist at time of dispensing unless their doctor has specified “no sub-
stitution” on their OxyNeo prescription, which would prevent the
pharmacist from dispensing the generic non‐tamper‐deterrent formu-
lation. In contrast, in Nova Scotia, pharmacists cannot substitute
OxyNeo with generic controlled‐release oxycodone.Despite these changes, and the associated controversies, little is
known about the uptake of OxyNeo and generic controlled‐release
oxycodone across the country. As policy‐makers and drug regulators
debate the role that tamper‐deterrent opioid formulations can have
in addressing opioid misuse and addiction, more information is needed
to understand shifts in prescribing patterns when these drugs are
reformulated. This study sought to determine the impact of changing
availability of controlled‐release oxycodone formulations on rates of
dispensing across Canada.2 | METHODS
We conducted a population‐based, serial cross‐sectional study of con-
trolled‐release oxycodone dispensing from community pharmacies
across Canada between October 2007 and April 2016. We used the
QuintilesIMS Compuscript database to quantify prescription volumes
for all long‐acting single‐agent oxycodone products dispensed over
the study period, including those covered by provincial public insur-
ance plans, private insurance companies and those purchased out of
pocket. This database provides projections for prescription quantities
at the provincial and national level based on data captured from a rep-
resentative sample of approximately 6000 community pharmacies
across the country. The geographic location of pharmacies, the dis-
tance between pharmacies and pharmacy size are all incorporated into
projections, which are conducted by QuintilesIMS at the level of drug
identification number. The quality of these data is continuously moni-
tored and verified by QuintilesIMS, and the Compuscript database is
regularly used for research purposes.1,16,17 We calculated the national
and provincial monthly rate of controlled‐release oxycodone dispens-
ing as the total number of tablets dispensed per 1000 population using
provincial population estimates from the 2006 Statistics Canada cen-
sus as our denominator. The national market share of each formulation
of controlled‐release oxycodone was calculated in each month over
the study period as the number of controlled‐release oxycodone tab-
lets that were dispensed for each formulation (OxyContin, OxyNeo,
and generic controlled‐release oxycodone). Finally, we estimated the
monthly proportion of controlled‐release oxycodone dispensing that
was for the generic formulations between December 2012 (when
generic formulations were first marketed) and the end of the study
522 GOMES ET AL.period. This was calculated as the total number of generic controlled‐
release oxycodone tablets dispensed divided by the total number of
controlled‐release oxycodone tablets dispensed nationally and strati-
fied by province.3 | RESULTS
A total of 780.2 million tablets for controlled‐release oxycodone were
dispensed across Canada over the study period, the majority of which
(457.2 million; 58.6%) were dispensed in Ontario. In October 2007, the
rate of controlled‐release oxycodone dispensing ranged from a low of
11.0 tablets per 100 population in Newfoundland and Labrador to 38.1
tablets per 100 population in Ontario (Figure 1). On a national level,
the rate of controlled‐release oxycodone dispensing was initially rela-
tively consistent, ranging between 22.4 and 29.3 tablets per 100 pop-
ulation between October 2007 and February 2012 (Figure 1). Upon
the introduction of a tamper‐deterrent formulation at that time, the
rate of controlled‐release oxycodone dispensing fell by 44.6% from
26.4 tablets per 100 population in February 2012 to 14.6 tablets per
100 population in April 2016. This fall was seen in most provinces
but was variable, ranging from 12.6% in Newfoundland and Labrador
(from 15.0 to 13.1 tablets per 100 population) to 58.5% in British
Columbia (from 16.5 to 6.8 tablets per 100 population). There was
no apparent rebound in dispensing after the introduction of generic
forms in late 2012 (Figure 1).
The national market shares of the different controlled‐release oxy-
codone products changed considerably over our study period. Upon its
introduction in February 2012, the tamper‐deterrent formulation
(OxyNeo) quickly replaced OxyContin, which was voluntarily with-
drawn from the market by its manufacturer9 (Figure 2). Following
the approval of generic non‐tamper‐deterrent forms of controlled‐
release oxycodone in December 2012, there was a modest uptakeFIGURE 1 Rate of controlled‐release oxycodone dispensing in Canada, stra
of controlled‐release oxycodone tablet dispensing per 100 population are r
population as name (average population in millions over the study period).
Saskatchewan (1.1 million); MB: Manitoba (1.2 million); ON: Ontario (13.2 m
Nova Scotia (0.5 million); NL: Newfoundland and Labrador (0.5 million); PEof these tablets such that 968 452 tablets (16.0% of all controlled‐
release oxycodone) were dispensed in Canada by July 2013
(Figure 2). Following this initial increase, the monthly volume of
generic forms of controlled‐release oxycodone remained stable,
ranging from 916 055 to 1 139 643 tablets (16.0% to 20.0% of all
controlled‐release oxycodone), over the remainder of the study
period (Figures 2 and 3).
The uptake of generic controlled‐release oxycodone varied con-
siderably across Canada, with a range of 1.6% to 55.0% across the
Canadian provinces in April 2016 (Figure 3). In Quebec, there was
rapid uptake of this formulation between February and April 2013,
after which the prevalence of generic dispensing remained relatively
stable until another rise occurred in early 2015. Overall, the prevalence
of generic dispensing reached 39.6% in April 2013, and by April 2016,
55.0% of all controlled‐release oxycodone tablets dispensed in Quebec
were for the generic formulation. We also observed considerable
uptake of generic controlled‐release oxycodone in British Columbia
(26.9% prevalence in April 2016), Ontario (16.7% prevalence in April
2016), and Newfoundland and Labrador (15.0% prevalence in April
2016). In all other provinces, the prevalence of generic controlled‐
release oxycodone dispensing remained relatively low, ranging
between 1.6% (Prince Edward Island) and 8.5% (New Brunswick) at
the end of our study period (Figure 3).4 | DISCUSSION
In this repeated cross‐sectional study of controlled‐release oxycodone
dispensing patterns across Canada, we found reductions in the rate of
dispensing of this drug after the introduction of a tamper‐deterrent
formulation in February 2012. We observed no obvious “rebound” in
national oxycodone dispensing after the introduction of generic non‐
tamper‐deterrent products later in the same year. However, we didtified by province. October 2007 to April 2016. Legend: monthly rates
eported nationally and by province. Provinces listed with approximate
BC: British Columbia (4.5 million); AB: Alberta (3.8 million); SK:
illion); QC: Quebec (8.0 million); NB: New Brunswick (0.8 million); NS:
I: Prince Edward Island (0.1 million); CAN: Canada (34.2 million)
FIGURE 3 Prevalence of generic controlled‐release oxycodone by Canadian province. December 2012 to April 2016. Legend: monthly proportion
of all controlled‐release oxycodone that is a generic formulation, reported as a percentage nationally and by province. Provinces listed with
approximate population as name (average population in millions over the study period). BC: British Columbia (4.5 million); AB: Alberta (3.8 million);
SK: Saskatchewan (1.1 million); MB: Manitoba (1.2 million); ON: Ontario (13.2 million); QC: Quebec (8.0 million); NB: New Brunswick (0.8 million);
NS: Nova Scotia (0.5 million); NL: Newfoundland and Labrador (0.5 million); PEI: Prince Edward Island (0.1 million); CAN: Canada (34.2 million)
FIGURE 2 Canadian market share of
controlled‐release oxycodone products.
October 2007 to April 2016. Legend: total
number of controlled‐release oxycodone
tablets dispensed nationally, stratified by
formulation. Formulations are as follows:
OxyContin = brand name, non‐tamper‐
deterrent controlled‐release oxycodone;
OxyNeo = brand name, tamper‐deterrent
controlled‐release oxycodone; generic CR
oxycodone = generic, non‐tamper‐deterrent
controlled‐release oxycodone
GOMES ET AL. 523observe considerable variation in the market shares achieved by the
generic forms across the Canadian provinces. The uptake was highest
in Quebec, followed by British Columbia, Ontario, and Newfoundland
and Labrador.
The observed reduction in dispensing of controlled‐release oxyco-
done at the time of the introduction of the tamper‐deterrent formula-
tion is aligned with changes in its listing on the majority of provincial
drug insurance plans in Canada, which either chose not to list this
new form of oxycodone on their formularies or listed it with excep-
tional access programs that required patients to meet a number ofstrict eligibility criteria before accessing the drug. Alberta, the only
province to list OxyNeo as a full benefit on their formulary, had only
minimal change in their dispensing patterns for controlled‐release oxy-
codone in February 2012 and was the province with the highest rate of
prescribing by the end of our study period. This suggests that public
drug funding and restricted reimbursement criteria influenced broad
patterns of oxycodone use across Canada. However, these products
have a relatively low cost, which might not deter their use in cases
where a patient is prescribed the product by their physician but do
not meet coverage criteria by a public or private drug insurance plan.
524 GOMES ET AL.Our study also suggests that the listing status of generic controlled‐
release oxycodone had a significant impact on the uptake of these
products. This is most apparent in Quebec where both brand (OxyNeo)
and generic controlled‐release oxycodone are listed similarly on the
drug formulary, with interchangeability and application of lowest
prices in effect. This listing creates a financial incentive for the generic
form of this drug to be dispensed, which may have led to the high
degree of controlled‐release oxycodone dispensed in the province
being for this non‐tamper‐deterrent form. Similarly, in British Colum-
bia, the provincial drug formulary reimbursed the generic form until
February 2015 when it was announced that the PharmaCare program
would no longer cover these products.18 Despite this announcement,
there was no change in the pattern of generic controlled‐release oxy-
codone in the province over the subsequent 14 months. This suggests
that reimbursement by the provincial drug program was not the only
driver of this higher use of generic controlled‐release oxycodone in
British Columbia and that patients continued to access these products
through private insurance coverage or cash purchase.
In Ontario and Newfoundland and Labrador, there was a relatively
high uptake of generic controlled‐release oxycodone despite these
products not being listed on the provincial drug formularies. In Ontario,
where oxycodone has historically been the dominant long‐acting opi-
oid on the market,1,16 it is possible that people who could no longer
access this product through the provincial drug formulary once restric-
tions were implemented around OxyNeo reimbursement, chose to pay
out of pocket for the cheaper, generic form of this drug, instead of
being switched to another long‐acting opioid product. Furthermore, it
is possible that there was a higher degree of OxyContin misuse (eg,
crushing and chewing tablets) in these provinces,19,20 which could
have led to increased desirability of the generic non‐tamper‐deterrent
form of oxycodone.4.1 | Strengths and limitations
The core strength of this study is our ability to report changes in the
dispensing patterns of all controlled‐release oxycodone prescriptions
dispensed over more than 8 years across Canada at the national and
provincial level. However, several limitations warrant emphasis. First,
we did not have access to patient‐level data and, therefore, could
not determine the degree to which generic controlled‐release oxyco-
done tablets were clustered at the individual level or rates of initiation
of these products. Second, the Compuscript database only captures
prescriptions dispensed from community pharmacies and, therefore,
cannot comment on patterns of hospital use of controlled‐release
oxycodone. Finally, we are not able to distinguish between publicly
and privately funded (ie, cash paid or privately insured) prescriptions.
However, given that generic forms of controlled‐release oxycodone
are generally not covered by public drug programs, this should have
limited impact on our interpretation of these results.5 | CONCLUSIONS
Changes to the availability and listing status of generic and brand name
formulations of controlled‐release oxycodone have led to importantchanges in both the rate of use of these products across Canada and
the relative market share of non‐tamper‐deterrent opioids. Importantly,
although the introduction of a tamper‐deterrent formulation in early
2012 led to considerable reductions in the rate of controlled‐release oxy-
codone dispensing, the marketing of generic non‐tamper‐deterrent
formulations later that year did not lead to any subsequent expansion
of the market. By 2016, 1 in 5 tablets for controlled‐release oxycodone
that were dispensed in Canada were for a generic, non‐tamper‐deterrent
form, and in several provinces, this was likely paid for by private insurers
or cash payments. The geographic variation in uptake of these products
suggests that provincial drug reimbursement policies—including
restrictions on access through public drug formularies—has influenced
these trends. In Canada, there was sufficient uptake of generic non‐
tamper‐deterrent formulations of oxycodone to justify further
research to determine if this has led to measurable changes in the
safety of oxycodone use in Canada. This is important as drug regula-
tors from around the world consider the role of tamper‐deterrent opi-
oid formulations in addressing the opioid crisis and seek to understand
how patent expiration and generic non‐tamper‐deterrent alternatives
will impact the prescribed opioid environment.
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